P Durrington

1.8k citations

16 papers · 1.4k indexed · 1 hit paper · h-index 10

Impact in

Clinical Biochemistry top 0.5%
- Paraoxonase enzyme and polymorphisms
Biochemistry top 5%
- Biochemical Acid Research Studies

Papers in ⓘ

Surgery 7
- Lipoproteins and Cardiovascular Health 6
Molecular Biology 3

Co-authors: Sharon Arrol (2 shared papers)Caroline A. Abbott (1 shared paper)Helen M. Colhoun (2 shared papers)Deepak Bhatnagar (2 shared papers)Handrean Soran (1 shared paper)Theresa M. Marteau (2 shared papers)J Yarwood (2 shared papers)R Cramb (2 shared papers)
Journals: Atherosclerosis (3 papers)Nephrology Dialysis Transplantation (1 paper)Clinical Therapeutics (1 paper)British Journal of Pharmacology (1 paper)Occupational Medicine (1 paper)
Partner nations: United Kingdom United States

In The Last Decade

P Durrington

15 papers receiving 1.3k citations

Hit Papers

align trajectories log scale

Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase 1993 · 689 citations

Peers

Countries citing papers authored by P Durrington

Since Specialization

Citations

This map shows the geographic impact of P Durrington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P Durrington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P Durrington more than expected).

Fields of papers citing papers by P Durrington

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P Durrington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P Durrington. The network helps show where P Durrington may publish in the future.

Co-authors

The 25 scholars most cited alongside P Durrington, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with P Durrington Line = papers co-authored together P Durrington links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work
1	Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase Atherosclerosis ·M MACKNESS, Sharon Arrol, Caroline A. Abbott, P Durrington Hit paper breakdown →	1993	689
2	Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study BMJ ·David Wood, A L Kinmonth, G. A. Davies, J Yarwood, Simon G. Thompson, S Pyke, Yih-Yih Kok, R Cramb, Claire L. Le Guen, Theresa M. Marteau, P Durrington	1994	297
3	Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial ACC Current Journal Review ·Helen M. Colhoun, D BETTERIDGE, P Durrington	2004	144
4	Hypercholesterolaemia and its management BMJ ·Deepak Bhatnagar, Handrean Soran, P Durrington	2008	124
5	Randomised controlled trial evaluating cardiovascular screening and intervention in general practice: principal results of British family heart study. Family Heart Study Group. PubMed ·P Durrington, Y. Kok-Kiong, A L Kinmonth, Clair Le Boutillier, Sdm Pyke, Theresa M. Marteau, R Cramb, S G Thompson, DA Wood, AL Kinmouth, J Yarwood	1994	86
6	Acute-pancreatitis: a complication of beta-blockade. BMJ ·P Durrington, S A Cairns	1982	22
7	Squalene synthase inhibitors British Journal of Pharmacology ·Valentine C. Menys, P Durrington	2003	16
8	Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: Results of a Markov model for UK costs using data registries Clinical Therapeutics ·Roberta Ara, Abdullah Pandor, Indra Tumur, Suzy Paisley, Alejandra Duenas, Robert W. Williams, A Wilkinson, P Durrington, J. Chilcott	2008	15
9	Molecular characterization of two patients with severe LCAT deficiency Nephrology Dialysis Transplantation ·Valentine Charlton-Menys, Livia Pisciotta, P Durrington, R H Neary, Colin D. Short, Laura Calabresi, S. Calandra, Stefano Bertolini	2007	11
10	Paraoxonase polymorphisms and self-reported chronic ill-health in farmers dipping sheep Occupational Medicine ·Andrew C. Povey, Mike Mackness, P Durrington, Martin Dippnall, A. E. Smith, Bharti Mackness, Nicola Cherry	2005	11
11	The european society of cardiology and the european atherosclerosis society (ESC/EAS) guidelines on the management of dyslipidemia Revista Española de Cardiología ·Željko Reiner, Alberico L. Catapano, Guy De Backer, Iain Graham, Marja‐Riitta Taskinen, Olov Wiklund, Stefan Agewall, Elisa Dessire Alegria, M.J. Chapman, P Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, J Kjekshus, Pasquale Perrone Filardi, David M. Wood, Robert F. Storey, Gina Riccardi	2011	3
12	Serum lipoprotein (a) (Lp(a)) levels in nephrotic syndrome (NS), CAPD patients and renal transplant (Tx) recipients Atherosclerosis ·C. E. Short, Nisar Anwar, P Durrington, Abdul Aleem Khan, Deepak Bhatnagar, Anthony Mbewu, N.P. Mallick, R Gokal	1991	3
13	ANY QUESTIONS BMJ ·P Durrington	1996	1
14	The relationship between serum butyrylcolinesterase activity, hypertriglyceridaemiaand insuliln sensitivity in diabetes mellitus Abbott Ca, Mackness Mi, Satyendra Kumar, Olukoga Ao, Christian Frizt Gordon, Sharon Arrol, Boulton Ajm, P Durrington	1993	1
15	Cost-effectiveness of atorvastatin (10mg) in patients with type 2 diabetes without coronary heart disease: CARDS trial analysis and extrapolation Oxford University Research Archive (ORA) (University of Oxford) ·Maria Raikou, Alistair McGuire, Helen M. Colhoun, John Betteridge, P Durrington, G. A. Hitman, A. Neil, Shona Livingstone, Margaret J. Thomason, Mike Mackness, Charlton-Menys, J Fuller, Cardsec Investigato	2005	1
16	Estimated 10-year cardiovascular risk in a British population: Results of a national screening project Atherosclerosis ·H. A. W. Neil, W.P.R.T. Perera, Jane Armitage, Andrew Farmer, David Mant, P Durrington	2007	1

About P Durrington

P Durrington is a scholar working on Surgery, Molecular Biology, Clinical Biochemistry, Public Health, Environmental and Occupational Health and Cardiology and Cardiovascular Medicine, having authored 16 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (6 papers), Paraoxonase enzyme and polymorphisms (3 papers), Health Promotion and Cardiovascular Prevention (3 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers), Blood Pressure and Hypertension Studies (2 papers), Cancer, Lipids, and Metabolism (2 papers), Cardiac Health and Mental Health (2 papers) and Pharmaceutical Economics and Policy (2 papers). The work is most often cited by research in Clinical Biochemistry (572 citations), Biochemistry (158 citations), Endocrinology, Diabetes and Metabolism (285 citations), Pharmacy (75 citations) and Biochemistry (84 citations). P Durrington has collaborated with scholars based in United Kingdom and United States. Frequent co-authors include Sharon Arrol, Caroline A. Abbott, Helen M. Colhoun, Deepak Bhatnagar, Handrean Soran, Theresa M. Marteau, J Yarwood, R Cramb, Yih-Yih Kok and Claire L. Le Guen. Their work appears in journals such as Atherosclerosis, Nephrology Dialysis Transplantation, Clinical Therapeutics, British Journal of Pharmacology and Occupational Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact